Advertisement
ABT or MDT or SYK
Which Stock Would AI Choose? Abbott Laboratories (ABT) vs. Medtronic (MDT) vs. Stryker (SYK) Stock Comparison
Key Takeaways
- Stryker (SYK) delivered the strongest organic revenue growth among the three at 10.3% for full-year 2025, with double-digit adjusted EPS growth and expanding margins, reinforcing its position at the high end of MedTech.
- Medtronic (MDT) is executing a notable turnaround, with its Cardiovascular segment recording its strongest growth in over a decade, driven by explosive demand for its pulsed field ablation (PFA) portfolio, and the stock has rallied over 30% year-to-date.
- Abbott Laboratories (ABT) faces near-term headwinds from weaker-than-expected Nutrition and Diagnostics performance, though its Medical Devices segment continues to deliver double-digit growth and its planned acquisition of Exact Sciences signals bold strategic ambition.
- Dividend reliability differentiates the group: Abbott has raised its dividend for 54 consecutive years, Medtronic for 48 years, while Stryker prioritizes reinvestment and acquisition-driven growth over a comparable dividend track record.
- Valuation sensitivity varies significantly — Stryker trades at a premium reflecting its superior growth profile, Medtronic sits at a more moderate multiple amid its turnaround, and Abbott's recent sell-off has compressed its valuation toward multi-year lows.
- All three companies are active participants in the fast-growing electrophysiology and pulsed field ablation market, making competitive dynamics in cardiac care a key factor for relative performance going forward.
Introduction
Abbott Laboratories (ABT), Medtronic (MDT), and Stryker (SYK) are three of the most closely watched names in the global medical technology industry. Together, they represent over $400 billion in combined market capitalization and span diagnostics, cardiovascular devices, orthopedics, surgical robotics, neuromodulation, and diabetes care. For investors and traders evaluating the MedTech space, understanding how these three giants compare across growth trajectories, margin profiles, risk exposures, and market sentiment is essential. This stock comparison examines each company's recent performance, strategic positioning, and relative momentum to provide a clear, data-driven snapshot of where they stand in the current market environment.
ABT Overview and Recent Performance
Abbott Laboratories is a diversified healthcare company operating across four segments: Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals. With full-year 2025 revenue of $44.3 billion, Abbott remains the largest of the three by sales. In recent weeks, however, sentiment around ABT has turned cautious. The company's fourth-quarter 2025 results, reported in late January 2026, revealed a revenue miss driven by an 8.9% decline in Nutrition sales and a 2.5% contraction in Diagnostics — the latter still grappling with the post-pandemic normalization of COVID-19 testing revenue and challenging market conditions in China tied to volume-based procurement (VBP) programs. The stock declined sharply following the report, approaching its 52-week low.
On the positive side, Abbott's Medical Devices segment grew 12.3% in the fourth quarter, fueled by double-digit gains in Electrophysiology, Heart Failure, Diabetes Care, and Rhythm Management. The company's continuous glucose monitoring (CGM) franchise, led by FreeStyle Libre, remains a powerful growth engine. Abbott also secured FDA approval for its Volt™ PFA System and CE Mark for its TactiFlex™ Duo Ablation Catheter, strengthening its competitive hand in the cardiac ablation market. Looking ahead, the planned $21 billion acquisition of Exact Sciences — expected to close in mid-2026 — represents a strategic pivot into cancer diagnostics and precision oncology. Abbott projects 2026 organic sales growth of 6.5% to 7.5% and adjusted EPS (earnings per share) of $5.55 to $5.80.
MDT Overview and Recent Performance
Medtronic plc, headquartered in Ireland, is the world's largest pure-play medical device company, with a portfolio spanning Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. MDT has emerged from a prolonged period of sluggish performance and is now displaying clear momentum. In its fiscal second quarter of 2026 (ended October 2025), Medtronic reported revenue of $9.0 billion, representing 5.5% organic growth, and raised its full-year guidance to approximately 5.5% organic revenue growth with adjusted EPS of $5.62 to $5.66.
The standout performer has been the Cardiac Ablation Solutions business, which surged 71% year-over-year — including 128% growth in the U.S. — on the strength of the company's pulsed field ablation (PFA) portfolio. The Cardiovascular segment recorded its fastest growth in over a decade, excluding the pandemic period. Medtronic also secured favorable CMS (Centers for Medicare & Medicaid Services) coverage for its Symplicity™ renal denervation procedure for hypertension, opening an addressable U.S. market of approximately 18 million people. The planned separation of the Diabetes business, announced in 2025, is expected to streamline the portfolio and improve company-wide margins. Goldman Sachs upgraded MDT from Sell to Neutral in November 2025, citing stronger product momentum and improving financial metrics. The stock has rallied meaningfully over the past several months.
SYK Overview and Recent Performance
Stryker Corporation, based in Michigan, specializes in orthopedics, medical and surgical equipment, and neurotechnology. SYK has been the growth leader among the three, delivering full-year 2025 revenue of $25.1 billion — an 11.2% reported increase and 10.3% organic growth. Adjusted EPS of $13.63 grew 11.8%, and the company expanded adjusted operating margin by 100 basis points for the second consecutive year, reaching 26.3%.
Stryker's MedSurg and Neurotechnology segment grew 15.7% for the full year, driven by strong demand for surgical instruments, endoscopy, and acute care products. In Orthopedics, organic growth of 9.5% was led by the Mako robotic-assisted surgery platform, which continues to gain adoption in knee and hip procedures. The company's divestiture of its spinal implants business has sharpened its focus on higher-growth areas. Stryker's fourth-quarter 2025 performance was particularly strong, with 11.0% organic revenue growth and adjusted operating margin of 30.2%. For 2026, management guided to organic sales growth of 8.0% to 9.5% and adjusted EPS of $14.90 to $15.10, signaling confidence in sustained momentum. The premium valuation SYK commands reflects the market's recognition of its consistent execution and above-peer growth.
Trending AI Robots
For traders seeking an automated, data-driven approach to navigating the MedTech sector, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots. Tickeron hosts hundreds of AI trading bots, each designed to trade specific tickers with distinct strategies, timeframes, and risk profiles. Only those bots demonstrating the strongest alignment with current market conditions earn a place in the Trending AI Robots section. Bots featured on this page span a wide range of performance statistics — some have achieved annualized returns exceeding 30%, while others focus on capital preservation with lower volatility. They vary in trading style from short-term momentum plays to trend-following strategies that hold positions for weeks or months. Each bot's detailed statistics, including win rates, trade counts, and drawdown metrics, are transparently displayed. For investors and traders who want to augment their decision-making with algorithmic precision, exploring the Trending AI Robots page may offer a valuable complement to traditional research methods.
Head-to-Head Comparison
When comparing ABT, MDT, and SYK, several structural contrasts emerge. In terms of growth trajectory, Stryker holds a clear advantage with organic revenue growth exceeding 10%, compared to Medtronic's mid-single-digit pace and Abbott's similar mid-single-digit rate. Stryker's higher growth is partially reflected in its premium valuation multiple. Medtronic, by contrast, offers a turnaround narrative — its PFA-driven acceleration and portfolio streamlining suggest potential for multiple expansion if execution remains strong. Abbott currently represents the value-oriented option in the group following its recent share price decline, though it carries near-term uncertainty around Nutrition and Diagnostics stabilization.
From a business model diversification standpoint, Abbott is the most varied, with meaningful exposure to branded generics, nutritionals, and diagnostics alongside devices — a structure that provides breadth but also introduces non-device cyclicality. Medtronic is the most comprehensive pure-play device company, with exposure across cardiovascular, neuroscience, surgical, and diabetes markets. Stryker is the most concentrated, with a dominant orthopedic franchise complemented by a growing MedSurg and Neurotechnology business.
Regarding risk factors, all three face tariff exposure and China-related headwinds, though Abbott's Diagnostics segment has been disproportionately affected by China's VBP policies. Medtronic carries execution risk tied to its Diabetes spin-off and Hugo RAS (robotic-assisted surgery) commercialization. Stryker's premium valuation makes it more vulnerable to compression if growth decelerates. On the capital returns front, both Abbott (54 years) and Medtronic (48 years) are distinguished dividend growers, while Stryker reinvests more aggressively into acquisitions and innovation.
Tickeron AI Verdict
Based on observable patterns in trend consistency, relative momentum, and earnings trajectory, Tickeron's AI framework would likely express a near-term preference for SYK among the three. Stryker's combination of sustained double-digit organic growth, consistent margin expansion, strong capital equipment demand, and a robust 2026 outlook provides the kind of trend stability that algorithmic models often favor. Medtronic represents a close second, with accelerating momentum in its Cardiovascular portfolio and improving sentiment among sell-side analysts — a profile that momentum-oriented AI strategies might find increasingly attractive. Abbott, while potentially offering the most compelling valuation entry point, currently displays mixed signals that could weigh on AI-driven confidence until greater clarity emerges around its Diagnostics and Nutrition segments and the Exact Sciences integration. As always, these assessments are probabilistic in nature and reflect a snapshot of current conditions rather than a definitive prediction of future outcomes.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABT’s FA Score shows that 2 FA rating(s) are green whileMDT’s FA Score has 1 green FA rating(s), and SYK’s FA Score reflects 1 green FA rating(s).
- ABT’s FA Score: 2 green, 3 red.
- MDT’s FA Score: 1 green, 4 red.
- SYK’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABT’s TA Score shows that 6 TA indicator(s) are bullish while MDT’s TA Score has 4 bullish TA indicator(s), and SYK’s TA Score reflects 6 bullish TA indicator(s).
- ABT’s TA Score: 6 bullish, 4 bearish.
- MDT’s TA Score: 4 bullish, 5 bearish.
- SYK’s TA Score: 6 bullish, 4 bearish.
Price Growth
ABT (@Medical/Nursing Services) experienced а +2.36% price change this week, while MDT (@Medical/Nursing Services) price change was +0.01% , and SYK (@Medical/Nursing Services) price fluctuated +3.25% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -5.78%. For the same industry, the average monthly price growth was -7.49%, and the average quarterly price growth was -21.89%.
Reported Earning Dates
ABT is expected to report earnings on Oct 21, 2026.
MDT is expected to report earnings on Sep 01, 2026.
SYK is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Medical/Nursing Services (-5.78% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| ABT | MDT | SYK | |
| Capitalization | 180B | 107B | 127B |
| EBITDA | 11.8B | 9.81B | 6.44B |
| Gain YTD | -16.214 | -11.882 | -5.532 |
| P/E Ratio | 33.35 | 22.31 | 38.22 |
| Revenue | 45.1B | 36.4B | 25.3B |
| Total Cash | N/A | 9.22B | N/A |
| Total Debt | 34B | 28B | 14.7B |
ABT | MDT | SYK | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 43 | 25 | 85 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 4 Undervalued | 3 Undervalued | 10 Undervalued | |
PROFIT vs RISK RATING 1..100 | 98 | 100 | 62 | |
SMR RATING 1..100 | 64 | 72 | 57 | |
PRICE GROWTH RATING 1..100 | 46 | 57 | 56 | |
P/E GROWTH RATING 1..100 | 11 | 63 | 80 | |
SEASONALITY SCORE 1..100 | 50 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MDT's Valuation (3) in the Medical Specialties industry is in the same range as ABT (4) and is in the same range as SYK (10). This means that MDT's stock grew similarly to ABT’s and similarly to SYK’s over the last 12 months.
SYK's Profit vs Risk Rating (62) in the Medical Specialties industry is somewhat better than the same rating for ABT (98) and is somewhat better than the same rating for MDT (100). This means that SYK's stock grew somewhat faster than ABT’s and somewhat faster than MDT’s over the last 12 months.
SYK's SMR Rating (57) in the Medical Specialties industry is in the same range as ABT (64) and is in the same range as MDT (72). This means that SYK's stock grew similarly to ABT’s and similarly to MDT’s over the last 12 months.
ABT's Price Growth Rating (46) in the Medical Specialties industry is in the same range as SYK (56) and is in the same range as MDT (57). This means that ABT's stock grew similarly to SYK’s and similarly to MDT’s over the last 12 months.
ABT's P/E Growth Rating (11) in the Medical Specialties industry is somewhat better than the same rating for MDT (63) and is significantly better than the same rating for SYK (80). This means that ABT's stock grew somewhat faster than MDT’s and significantly faster than SYK’s over the last 12 months.
| ABT | MDT | SYK | |
|---|---|---|---|
| RSI ODDS (%) | 3 days ago 53% | N/A | 3 days ago 46% |
| Stochastic ODDS (%) | 3 days ago 45% | 3 days ago 56% | 3 days ago 63% |
| Momentum ODDS (%) | 3 days ago 51% | 3 days ago 59% | 3 days ago 62% |
| MACD ODDS (%) | 3 days ago 46% | 3 days ago 64% | 3 days ago 49% |
| TrendWeek ODDS (%) | 3 days ago 51% | 3 days ago 53% | 3 days ago 54% |
| TrendMonth ODDS (%) | 3 days ago 48% | 3 days ago 46% | 3 days ago 47% |
| Advances ODDS (%) | 3 days ago 54% | 3 days ago 51% | 3 days ago 56% |
| Declines ODDS (%) | 13 days ago 54% | 5 days ago 57% | 5 days ago 53% |
| BollingerBands ODDS (%) | 3 days ago 53% | 3 days ago 70% | 3 days ago 55% |
| Aroon ODDS (%) | 3 days ago 48% | 3 days ago 37% | 3 days ago 47% |
Advertisement
MDT and
Correlation & Price change
A.I.dvisor indicates that over the last year, MDT has been loosely correlated with SYK. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if MDT jumps, then SYK could also see price increases.
SYK and
Correlation & Price change
A.I.dvisor indicates that over the last year, SYK has been loosely correlated with ISRG. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if SYK jumps, then ISRG could also see price increases.